{"entity":{"id":"nct05231850","kind":"trial","name":"A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI.","aka":[],"tldr":"A phase 2 trial of tislelizumab in colorectal cancer, run by The First Affiliated Hospital of Zhengzhou University, not yet recruiting.","summary":"A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI. is a phase 2, interventional study registered as NCT05231850 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 70 participants, started 2022-03-01 and due to reach its primary completion in 2023-09-01. Interventions recorded: Tislelizumab. Conditions listed: Colon Cancer. Primary outcome: Primary End point: Disease Free survival [ Time Frame: 3 years ]. Colorectal eligibility wording from the registry: \", any T, N1 or N2, M0) adenocarcinoma of the colon (as defined by the presence of the inferior pole of the tumour above the peritoneal reflection - that is, at least 15 cm from the anal margin)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05231850","url":"https://clinicaltrials.gov/study/NCT05231850"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05231850","phase":"2","setting":"A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With High-risk Stage II and Stage III Colon Cancer and Deficient Mismatch Repair or Microsatellite Instability.","sponsor":"The First Affiliated Hospital of Zhengzhou University","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05231850/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}